Phase 4 N=1 Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
Glaucoma
Primary: Mean Change From Baseline in Diurnal IOP at Week 6
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Osteoporosis
Primary: Number of Participants With Adverse Events — 7; 6; 0; 1 Participants
Phase 1 N=13 A Study of LY3015014 in Healthy Participants With High Cholesterol
Healthy Volunteers · Hypercholesterolemia
Primary: Number of Participants With One or More Other Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs) — 3; 1; 0; 0 Participants
N/A N=128 Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery
Laparoscopic Colectomy
Primary: Medical Recovery (Defined as Pain Sufficient Controlled by Oral Analgesia, Fully Mobile Patients or at Least as Mobile as at Admission and Tolerance of the Patient of…
Phase 2 N=87 The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Determine Feasibility as Measured by Rates of Recruitment. — 66 percentage of participants
Phase 4 N=107 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
HIV-1 Infection
Primary: The Proportion of Patients Who Can Achieve of Less Than 20 HIV RNA Copies Per ml at Week 48 of Both Arms. — 41; 36 Participants
Phase 3 N=746 Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 30 — -1.88; -1.42 Percent A1C — p=< 0.001
Phase 4 N=20 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
Actinic Keratosis
Primary: Number of Participants With Adverse Events — 12; 11; 6; 3 Participants
Phase 1 N=36 Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1066.11; 1117.31 ng/ml
Phase 1 N=30 Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1730; 1230; 1110 ng/mL
Phase 1 N=16 Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)
Human Immunodeficiency Virus-1 (HIV-1)
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439 — 28.6; 31.9; 35.5; 29.1 µM*h
Phase 3 N=851 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 — 50.7; 60.9; 65.0 percentage of participants — p=0.005
Phase 2 N=32 Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
Prostate Cancer
Primary: Pharmocodynamically Optimal Dose (POD) of Rapamycin as Determined by Number of Participants With Greater Than or Equal to 60% Tumor S6 Kinase Inhibition by…
N/A N=171 Web and Shared Decision Making for Reserve/National Guard Women's PTSD Care
PTSD
Primary: Number of Participants With VA Mental Health Care Engagement — 40; 30; 28; 28 Participants — p=0.1996
Phase 1 N=17 AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Colorectal Cancer · Colorectal Neoplasms · Colorectal Carcinoma
Primary: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) — 6; 9 Participants